Cargando…
Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
Quantitative systems pharmacology (QSP), a mechanistically oriented form of drug and disease modeling, seeks to address a diverse set of problems in the discovery and development of therapies. These problems bring a considerable amount of variability and uncertainty inherent in the nonclinical and c...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617832/ https://www.ncbi.nlm.nih.gov/pubmed/31087533 http://dx.doi.org/10.1002/psp4.12426 |
_version_ | 1783433781226504192 |
---|---|
author | Helmlinger, Gabriel Sokolov, Victor Peskov, Kirill Hallow, Karen M. Kosinsky, Yuri Voronova, Veronika Chu, Lulu Yakovleva, Tatiana Azarov, Ivan Kaschek, Daniel Dolgun, Artem Schmidt, Henning Boulton, David W. Penland, Robert C. |
author_facet | Helmlinger, Gabriel Sokolov, Victor Peskov, Kirill Hallow, Karen M. Kosinsky, Yuri Voronova, Veronika Chu, Lulu Yakovleva, Tatiana Azarov, Ivan Kaschek, Daniel Dolgun, Artem Schmidt, Henning Boulton, David W. Penland, Robert C. |
author_sort | Helmlinger, Gabriel |
collection | PubMed |
description | Quantitative systems pharmacology (QSP), a mechanistically oriented form of drug and disease modeling, seeks to address a diverse set of problems in the discovery and development of therapies. These problems bring a considerable amount of variability and uncertainty inherent in the nonclinical and clinical data. Likewise, the available modeling techniques and related software tools are manifold. Appropriately, the development, qualification, application, and impact of QSP models have been similarly varied. In this review, we describe the progressive maturation of a QSP modeling workflow: a necessary step for the efficient, reproducible development and qualification of QSP models, which themselves are highly iterative and evolutive. Furthermore, we describe three applications of QSP to impact drug development; one supporting new indications for an approved antidiabetic clinical asset through mechanistic hypothesis generation, one highlighting efficacy and safety differentiation within the sodium‐glucose cotransporter‐2 inhibitor drug class, and one enabling rational selection of immuno‐oncology drug combinations. |
format | Online Article Text |
id | pubmed-6617832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66178322019-07-16 Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development Helmlinger, Gabriel Sokolov, Victor Peskov, Kirill Hallow, Karen M. Kosinsky, Yuri Voronova, Veronika Chu, Lulu Yakovleva, Tatiana Azarov, Ivan Kaschek, Daniel Dolgun, Artem Schmidt, Henning Boulton, David W. Penland, Robert C. CPT Pharmacometrics Syst Pharmacol Reviews Quantitative systems pharmacology (QSP), a mechanistically oriented form of drug and disease modeling, seeks to address a diverse set of problems in the discovery and development of therapies. These problems bring a considerable amount of variability and uncertainty inherent in the nonclinical and clinical data. Likewise, the available modeling techniques and related software tools are manifold. Appropriately, the development, qualification, application, and impact of QSP models have been similarly varied. In this review, we describe the progressive maturation of a QSP modeling workflow: a necessary step for the efficient, reproducible development and qualification of QSP models, which themselves are highly iterative and evolutive. Furthermore, we describe three applications of QSP to impact drug development; one supporting new indications for an approved antidiabetic clinical asset through mechanistic hypothesis generation, one highlighting efficacy and safety differentiation within the sodium‐glucose cotransporter‐2 inhibitor drug class, and one enabling rational selection of immuno‐oncology drug combinations. John Wiley and Sons Inc. 2019-06-11 2019-06 /pmc/articles/PMC6617832/ /pubmed/31087533 http://dx.doi.org/10.1002/psp4.12426 Text en 2019 Astrazeneca Company. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology & Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Reviews Helmlinger, Gabriel Sokolov, Victor Peskov, Kirill Hallow, Karen M. Kosinsky, Yuri Voronova, Veronika Chu, Lulu Yakovleva, Tatiana Azarov, Ivan Kaschek, Daniel Dolgun, Artem Schmidt, Henning Boulton, David W. Penland, Robert C. Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development |
title | Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development |
title_full | Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development |
title_fullStr | Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development |
title_full_unstemmed | Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development |
title_short | Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development |
title_sort | quantitative systems pharmacology: an exemplar model‐building workflow with applications in cardiovascular, metabolic, and oncology drug development |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617832/ https://www.ncbi.nlm.nih.gov/pubmed/31087533 http://dx.doi.org/10.1002/psp4.12426 |
work_keys_str_mv | AT helmlingergabriel quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT sokolovvictor quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT peskovkirill quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT hallowkarenm quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT kosinskyyuri quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT voronovaveronika quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT chululu quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT yakovlevatatiana quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT azarovivan quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT kaschekdaniel quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT dolgunartem quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT schmidthenning quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT boultondavidw quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment AT penlandrobertc quantitativesystemspharmacologyanexemplarmodelbuildingworkflowwithapplicationsincardiovascularmetabolicandoncologydrugdevelopment |